Brief: Hungary's Richter enters deal with Myovant Sciences on uterine fibroid medicine

Richter Gedeon Vegyeszeti Gyar Nyrt

31/03/2020 07:06

March 31 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt
 GDRB.BU :
    * ENTERS INTO EXCLUSIVE AGREEMENT WITH MYOVANT SCIENCES TO
SELL
RELUGOLIX COMBINATION TABLET FOR UTERINE FIBROIDS AND
ENDOMETRIOSIS IN CERTAIN TERRITORIES OUTSIDE THE U.S.
    * AGREEMENT WITH MYOVANT SCIENCES COVERS EUROPE, THE
COMMONWEALTH
OF INDEPENDENT STATES INCLUDING RUSSIA, LATIN AMERICA, AUSTRALIA
AND NEW ZEALAND
    * UNDER THE AGREEMENT, MYOVANT WILL RECEIVE AN UPFRONT
PAYMENT OF
$40 MILLION
    * MYOVANT IS ELIGIBLE TO RECEIVE UP TO $40 MILLION IN
REGULATORY
MILESTONES AND $107.5 MILLION IN SALES RELATED MILESTONES, AND
TIERED ROYALTIES ON NET SALES FOLLOWING REGULATORY APPROVAL
    * MYOVANT RETAINS ALL RIGHTS TO RELUGOLIX COMBINATION TABLET
IN
THE U.S., AS WELL AS RIGHTS TO RELUGOLIX IN OTHER THERAPEUTIC
AREAS OUTSIDE OF WOMEN'S HEALTH
    * MYOVANT HAS GRANTED RICHTER AN OPTION TO COLLABORATE ON
RELUGOLIX COMBINATION TABLET FOR FUTURE INDICATIONS IN WOMEN'S
HEALTH OTHER THAN FERTILITY

Further company coverage:  GDRB.BU  MYOV.N 

 (Reporting by Gergely Szakacs)
 ((gergely.szakacs@reuters.com ; https://twitter.com/szakacsg ;
+36 1 882 3606 ;
https://www.reuters.com/journalists/gergely-szakacs))